Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.

[1]  Douglas C. Miller,et al.  Treatment and Survival of Low-Grade Astrocytoma in Adults--1977–1988 , 1992 .

[2]  S. Steinberg,et al.  Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Prados,et al.  Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. , 1991, International journal of radiation oncology, biology, physics.

[4]  S. Gebarski,et al.  Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas. , 1990, International Journal of Radiation Oncology, Biology, Physics.

[5]  J. Vander,et al.  The ocular effects of intracarotid bromodeoxyuridine and radiation therapy in the treatment of malignant glioma. , 1990, Ophthalmology.

[6]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[7]  C. Daumas-Duport,et al.  Radiation therapy in the management of low-grade supratentorial astrocytomas. , 1989, Journal of neurosurgery.

[8]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.

[9]  S. Gebarski,et al.  Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas. , 1988, Journal of neurosurgery.

[10]  P. Gutin,et al.  Reoperation for recurrent glioblastoma and anaplastic astrocytoma. , 1987, Neurosurgery.

[11]  J. Piepmeier,et al.  Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. , 1987, Journal of neurosurgery.

[12]  A. Fornace,et al.  Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. , 1987, International journal of radiation oncology, biology, physics.

[13]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[14]  E. M. Levin,et al.  Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. , 1984, International journal of radiation oncology, biology, physics.

[15]  T. Kinsella,et al.  The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers. , 1984, International journal of radiation oncology, biology, physics.

[16]  D. Nelson,et al.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. , 1983, International journal of radiation oncology, biology, physics.

[17]  M. Feldstein,et al.  Introduction--workshop on characterizing the effects of endocrine disruptors on human health at environmental exposure levels , 1999, Environmental health perspectives.

[18]  P. Sonneveld,et al.  Pharmacology of bromodeoxyuridine (NSC 38297) given by peripheral venous infusion , 1982 .

[19]  W. Lewin,et al.  A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. , 1981, British Journal of Cancer.

[20]  W. Wara,et al.  A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. , 1979, Journal of neurosurgery.

[21]  B. Goz.  The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. , 1977, Pharmacological reviews.

[22]  J. Brown,et al.  Comparison of intravenous and intra-arterial pyrimidine infusion as a means of radiosensitizing tumors in vivo. , 1977, Radiology.

[23]  D. Norman,et al.  Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. , 1977, Journal of neurosurgery.

[24]  T. H. Newton,et al.  Computed tomography in the evaluation of malignant glioma before and after therapy. , 1976, Radiology.

[25]  W. Szybalski.  X-ray sensitization by halopyrimidines. , 1974, Cancer chemotherapy reports.

[26]  K. Sano,et al.  Radiosensitization of brain tumor cells with a thymidine analogue (bromouridine). , 1968, Journal of neurosurgery.

[27]  R. Johns,et al.  Enhancement of radiation-induced mitotic inhibition by BUdR incorporation in L-cells. , 1966, Radiation research.

[28]  B. Djordjevic,et al.  Chromosomal Aberrations in Synchronized Mammalian Cells treated with 5-Bromodeoxyuridine and irradiated by Ultra-violet Light , 1965, Nature.

[29]  S. Bond,et al.  The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine, and 5-iododeoxycytidine in man. , 1963, Cancer research.

[30]  J. Kriss,et al.  The distribution and fate of bromodeoxyuridine and bromodeoxycytidine in the mouse and rat. , 1962, Cancer research.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  M. John,et al.  Chemoradiation : an integrated approach to cancer treatment , 1993 .

[33]  R. Davis,et al.  Grading of Gliomas , 1989 .

[34]  W. S. Fields,et al.  Primary Brain Tumors , 2011, Springer New York.

[35]  J. Levi.  Cancer: Principles and Practice of Oncology, 2nd Edition, Vincent T. de Vita, Samuel Hellman, Steven A. Rosenberg (Eds.). J.B. Lippincott, Philadelphia (1985), 2344, (Aust. Distr. Harper and Row, Sydney). $310.00 ISBN 06-6508915, illustrated , 1987 .

[36]  D. Cox.  Regression Models and Life-Tables , 1972 .

[37]  K. Sano,et al.  Experimental and clinical studies of radiosensitizers in brain tumors, with special reference to BUdR-antimetabolite continuous regional infusion-radiation therapy (BAR therapy). , 1965, Neurologia medico-chirurgica.